SEC Tracker
Get the app

Alaunos Therapeutics TCRT

Alaunos Therapeutics failed to meet Nasdaq rules

Item 3.01 Listing standards notice

Form
8-K
Filed
Importance
Major
  1. Received notice of non-compliance with Nasdaq's $2.5M stockholders equity rule
  2. Completed acquisition of Velaris Therapeutics and raised $350M in financing
  3. Nasdaq will monitor compliance with equity rule through 2026 annual report

Written from the 8-K on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Alaunos Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. BioCardia BCDA public float $10M, Jun 30, 2025
  2. Raphael Pharmaceutical RAPH public float $9M, Jun 30, 2025
  3. Traws Pharma ONTX public float $10M, Jun 30, 2025
  4. Mannatech MTEX public float $10M, Jun 30, 2025
  5. Bioxytran BIXT public float $9M, Jun 30, 2025